Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular maps of diseases from omics data and network embeddings.

NPJ systems biology and applications·2026
Same author

AIntibody: an experimentally validated in silico antibody discovery design challenge.

Nature biotechnology·2024
Same author

Structural Characterization of Peptide Antibodies.

Methods in molecular biology (Clifton, N.J.)·2024
Same author

IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition.

Frontiers in immunology·2024
Same author

DiscoTope-3.0: improved B-cell epitope prediction using inverse folding latent representations.

Frontiers in immunology·2024
Same author

Variability analysis of LC-MS experimental factors and their impact on machine learning.

GigaScience·2023

Related Experiment Video

Updated: Aug 22, 2025

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.0K

A Computational Pipeline for Predicting Cancer Neoepitopes.

Anna-Lisa Schaap-Johansen1, Paolo Marcatili2

  • 1Department of Health Technology, Technical University of Denmark, ØrstedsPlads, Lyngby, Denmark.

Methods in Molecular Biology (Clifton, N.J.)
|November 8, 2022
PubMed
Summary

MuPeXI identifies tumor-specific peptides as potential neoepitopes using VCF files and HLA types. This guide details data processing and running MuPeXI locally or via a web server for cancer immunotherapy research.

Keywords:
ImmunotherapyMutationNeoantigensNeoepitopesPredictionSequencingVariant calling

More Related Videos

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

11.7K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K

Related Experiment Videos

Last Updated: Aug 22, 2025

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.0K
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

11.7K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K

Area of Science:

  • Computational biology
  • Immunoinformatics
  • Cancer immunology

Background:

  • Neoepitopes are crucial targets for cancer immunotherapies.
  • Accurate identification of tumor-specific neoepitopes is essential for personalized cancer vaccines.
  • Existing tools require specific data formats and processing pipelines.

Purpose of the Study:

  • To describe a data processing pipeline for the Mutant Peptide eXtractor and Informer (MuPeXI) program.
  • To provide instructions for running MuPeXI both locally and as a web server.
  • To facilitate the identification and assessment of tumor-specific neoepitopes.

Main Methods:

  • Utilized Variant Call Format (VCF) files as primary input.
  • Incorporated Human Leukocyte Antigen (HLA) typing data.
  • Optionally integrated gene expression profiles for enhanced neoepitope assessment.
  • Developed a data processing pipeline compatible with MuPeXI.

Main Results:

  • A standardized pipeline for preparing input data for MuPeXI was established.
  • Successful execution of MuPeXI was demonstrated both locally and on a web server.
  • The pipeline enables efficient processing of VCF and HLA data for neoepitope prediction.

Conclusions:

  • The described pipeline simplifies the use of MuPeXI for neoepitope identification.
  • This facilitates research in personalized cancer vaccines and immunotherapies.
  • MuPeXI, with this pipeline, is a valuable tool for cancer immunology research.